These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2155 related items for PubMed ID: 27651331

  • 1. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
    Frías JP, Guja C, Hardy E, Ahmed A, Dong F, Öhman P, Jabbour SA.
    Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
    [Abstract] [Full Text] [Related]

  • 2. Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial.
    Jabbour SA, Frías JP, Hardy E, Ahmed A, Wang H, Öhman P, Guja C.
    Diabetes Care; 2018 Oct; 41(10):2136-2146. PubMed ID: 30082326
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
    Ahrén B, Masmiquel L, Kumar H, Sargin M, Karsbøl JD, Jacobsen SH, Chow F.
    Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial.
    Jabbour SA, Frías JP, Ahmed A, Hardy E, Choi J, Sjöström CD, Guja C.
    Diabetes Care; 2020 Oct; 43(10):2528-2536. PubMed ID: 32816874
    [Abstract] [Full Text] [Related]

  • 5. Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.
    Mathieu C, Ranetti AE, Li D, Ekholm E, Cook W, Hirshberg B, Chen H, Hansen L, Iqbal N.
    Diabetes Care; 2015 Nov; 38(11):2009-17. PubMed ID: 26246458
    [Abstract] [Full Text] [Related]

  • 6. Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION-8 randomized controlled trial.
    Frías JP, Hardy E, Ahmed A, Öhman P, Jabbour S, Wang H, Guja C.
    Diabetes Obes Metab; 2018 Jun; 20(6):1520-1525. PubMed ID: 29573139
    [Abstract] [Full Text] [Related]

  • 7. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
    Ludvik B, Giorgino F, Jódar E, Frias JP, Fernández Landó L, Brown K, Bray R, Rodríguez Á.
    Lancet; 2021 Aug 14; 398(10300):583-598. PubMed ID: 34370970
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
    Aroda VR, Bain SC, Cariou B, Piletič M, Rose L, Axelsen M, Rowe E, DeVries JH.
    Lancet Diabetes Endocrinol; 2017 May 14; 5(5):355-366. PubMed ID: 28344112
    [Abstract] [Full Text] [Related]

  • 9. Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year.
    Lundkvist P, Pereira MJ, Katsogiannos P, Sjöström CD, Johnsson E, Eriksson JW.
    Diabetes Obes Metab; 2017 Sep 14; 19(9):1276-1288. PubMed ID: 28345814
    [Abstract] [Full Text] [Related]

  • 10. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial.
    Ludvik B, Frías JP, Tinahones FJ, Wainstein J, Jiang H, Robertson KE, García-Pérez LE, Woodward DB, Milicevic Z.
    Lancet Diabetes Endocrinol; 2018 May 14; 6(5):370-381. PubMed ID: 29483060
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
    Bergenstal RM, Wysham C, Macconell L, Malloy J, Walsh B, Yan P, Wilhelm K, Malone J, Porter LE, DURATION-2 Study Group.
    Lancet; 2010 Aug 07; 376(9739):431-9. PubMed ID: 20580422
    [Abstract] [Full Text] [Related]

  • 12. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study.
    Weber MA, Mansfield TA, Cain VA, Iqbal N, Parikh S, Ptaszynska A.
    Lancet Diabetes Endocrinol; 2016 Mar 07; 4(3):211-220. PubMed ID: 26620248
    [Abstract] [Full Text] [Related]

  • 13. Randomized, Double-Blind Trial of Triple Therapy With Saxagliptin Add-on to Dapagliflozin Plus Metformin in Patients With Type 2 Diabetes.
    Matthaei S, Catrinoiu D, Celiński A, Ekholm E, Cook W, Hirshberg B, Chen H, Iqbal N, Hansen L.
    Diabetes Care; 2015 Nov 07; 38(11):2018-24. PubMed ID: 26324329
    [Abstract] [Full Text] [Related]

  • 14. Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial.
    Matthaei S, Bowering K, Rohwedder K, Grohl A, Parikh S, Study 05 Group.
    Diabetes Care; 2015 Mar 07; 38(3):365-72. PubMed ID: 25592197
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial.
    Dandona P, Mathieu C, Phillip M, Hansen L, Griffen SC, Tschöpe D, Thorén F, Xu J, Langkilde AM, DEPICT-1 Investigators.
    Lancet Diabetes Endocrinol; 2017 Nov 07; 5(11):864-876. PubMed ID: 28919061
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial.
    Bailey CJ, Morales Villegas EC, Woo V, Tang W, Ptaszynska A, List JF.
    Diabet Med; 2015 Apr 07; 32(4):531-41. PubMed ID: 25381876
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Frias JP, Nauck MA, Van J, Kutner ME, Cui X, Benson C, Urva S, Gimeno RE, Milicevic Z, Robins D, Haupt A.
    Lancet; 2018 Nov 17; 392(10160):2180-2193. PubMed ID: 30293770
    [Abstract] [Full Text] [Related]

  • 18. Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study.
    Jabbour SA, Frías JP, Guja C, Hardy E, Ahmed A, Öhman P.
    Diabetes Obes Metab; 2018 Jun 17; 20(6):1515-1519. PubMed ID: 29316164
    [Abstract] [Full Text] [Related]

  • 19. Twice-daily dapagliflozin co-administered with metformin in type 2 diabetes: a 16-week randomized, placebo-controlled clinical trial.
    Schumm-Draeger PM, Burgess L, Korányi L, Hruba V, Hamer-Maansson JE, de Bruin TW.
    Diabetes Obes Metab; 2015 Jan 17; 17(1):42-51. PubMed ID: 25200570
    [Abstract] [Full Text] [Related]

  • 20. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.
    Jabbour SA, Hardy E, Sugg J, Parikh S, Study 10 Group.
    Diabetes Care; 2014 Jan 17; 37(3):740-50. PubMed ID: 24144654
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 108.